Juan Carlos Torre Alonso-rekin lankidetzan egindako argitalpenak (15)

2023

  1. Expert recommendations for the use of apremilast in psoriatic arthritis

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 34-44

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  2. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1103 Clinical Sciences

    Arthritis Research and Therapy, Vol. 21, Núm. 1

  3. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2018

  1. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis

    Reumatologia Clinica, Vol. 14, Núm. 5, pp. 254-268

2017

  1. Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 19, Núm. 1

2016

  1. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

2014

  1. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis

    Pharmacogenomics, Vol. 15, Núm. 14, pp. 1763-1769

  2. Standards of care for patients with spondyloarthritis

    Rheumatology International, Vol. 34, Núm. 2, pp. 165-170

2013

  1. Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER

    Reumatologia Clinica, Vol. 9, Núm. 4, pp. 221-225

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2009

  1. First signs and symptoms of spondyloarthritis-data from an inception cohort with a disease course of two years or less (REGISPONSER-Early)

    Rheumatology, Vol. 48, Núm. 4, pp. 404-409